Population
Truncated form of Kir6.2 (expressed independently of SUR1) and an ATP-insensitive mutant (K185Q)
Design
Preclinical
Authors
Loading...
Phentolamine's direct Kir6.2 blockade warrants caution in cardiac applications; leaves open clinical relevance pending human studies.
Phentolamine blocks KATP channels by directly interacting with the Kir6.2 pore-forming subunit rather than the SUR1 regulator, providing insight into its mechanism of action in both pancreatic beta cells and the heart.
Proks et al. (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: